Clearstead Advisors’s Humacyte HUMA Stock Holding History

Clearstead Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7	Closed	-$15	–	3158
2025 Q2	$15	Buy	+7	New	+$13	﹤0.01%	2716

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clearstead Advisors's HUMA Position: Q3 2025 in Review

Clearstead Advisors sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 7 shares — an estimated $15 sold.

Clearstead Advisors first reported a position in HUMA in Q2 2025 and held it in 1 quarter. The position peaked at $15 in Q2 2025. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

Clearstead Advisors reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 7 Humacyte shares in Q3 2025, an estimated $15.
Clearstead Advisors first reported a position in Humacyte in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Humacyte position peaked at $15 in Q2 2025.
141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.